Keywords: boeh, ing, vitae, sign, metabolics, deal, german
Boeh Ing and Vitae sign metabolics R&D deal
Article | 22 October 2007
German privately-owned drug maker Boehringer Ingelheim and USA-based Vitae Pharmaceuticals have entered into a deal to develop and commercialize a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
